[Zn2(salicylaldehyde-4-chlorbenzoyl hydrazone(-2H))2(water)2]*[Zn2(salicylaldehyde-chlorbenzoyl hydrazone(-2H))2(DMSO)4] | 1311320-46-3

• 英文名称: [Zn2(salicylaldehyde-4-chlorbenzoyl hydrazone(-2H))2(water)2]*[Zn2(salicylaldehyde-chlorbenzoyl hydrazone(-2H))2(DMSO)4]
• CAS: 1311320-46-3
• 化学式: C₂₈H₂₂Cl₂N₄O₆Zn₂*C₃₆H₄₂Cl₂N₄O₈S₄Zn₂
• 分子量: 1700.89
• InChiKey: WCUVRUYTKHPZKG-UHFFFAOYSA-F

计算性质

• 辛醇/水分配系数(LogP)：
  None
• 重原子数：
  None
• 可旋转键数：
  None
• 环数：
  None
• sp3杂化的碳原子比例：
  None
• 拓扑面积：
  None
• 氢给体数：
  None
• 氢受体数：
  None

反应信息

• 作为产物：
  描述：

  [Zn2Cl2(salicylaldehyde-4-chlorbenzoyl hydrazone(-H))2] 、 二甲基亚砜 以 二甲基亚砜 、 丙酮 为溶剂， 生成 [Zn2(salicylaldehyde-4-chlorbenzoyl hydrazone(-2H))2(water)2]*[Zn2(salicylaldehyde-chlorbenzoyl hydrazone(-2H))2(DMSO)4]
  参考文献：
  名称：

  Binuclear zinc(II) complexes with the anti-inflammatory compounds salicylaldehyde semicarbazone and salicylaldehyde-4-chlorobenzoyl hydrazone (H2LASSBio-1064)

  摘要：

  Complexes [Zn-2(HL1)(2)(CH3COO)(2)] (1) and [Zn-2(L-2)(2)] (2) were synthesized with salicylaldehyde semicarbazone (H2L1) and salicylaldehyde-4-chlorobenzoyl hydrazone (H(2)LASSBio-1064, H2L2), respectively. The crystal structure of (1) was determined. Upon recrystallization of previously prepared [Zn-2(HL2)(2)(Cl)(2)] (3) in 1:9 DMSO:acetone crystals of [Zn-2(L-2)(2)(H2O)(2)]center dot[Zn-2(L-2)(2)(DMSO)(4)] (3a) were obtained. The crystal structure of 3a was also determined. All crystal structures revealed the presence of phenoxo-bridged binuclear zinc(II) complexes. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.poly.2011.04.024